BY Capital GmbH Co. KG — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Cytosolixcytosolix.cominJun 2023SEC filingmedium confidence
Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue.
AI & Machine LearningBiotechDeep TechTolland, US
John Deacon(Executive Officer, Director)Colin J. Foster(Executive Officer, Director)
BoardAlex Brunicki(Director)
Board seatJason Whitmire· per SEC Form D · $6.6M raise · filed Jun 2023
Co-investorsBackedBlueYard Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.